Close backs Dexela’s development
Article Date: May 16 2006
Dexela, the developer of a new 3D scanner for the detection of breast cancer, has secured £1.6 million of development capital from Close Venture Management and Oxford Technology.
Investing via a range of its VCTs, Close was the largest investor in the funding round, providing £1.2 million in total, with Oxford adding a further £250,000. Dexela will use the cash to further develop and commercialise its technologies.
‘Analogue screening mammography has been used for breast imaging for the past 40 years, with minimal development in technology and continued issues with high false positive results and missed cancers,’ notes Dexela’s Dr Ed Bullard. ‘We believe that the use of low-dose 3D breast imaging will overcome many of these issues and lead to significant improvements in the detection of cancers.’
‘At the moment if you want to up the resolution of a screening you have to increase the X-Ray dose. That’s dangerous and not suitable except in emergency cases,’ Oxford Technology’s Matthew Frohn elaborates. ‘So far, Dexela’s technology has been shown to offer a way around this.’
In addition to the obvious health benefits, Close’s Dr Andrew Elder also highlights a strong commercial case for backing such technologies. ‘Sales of digital machines are expected to drive the mammography market up to more than £1 billion in 2008.’
